Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia

N-Acetyl-Aspartyl-Glutamate in Brain Health and Disease

(2022) Cecilie Morland et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy

(2021) Hannah E. Goldstein et al.   Frontiers in Neurology

Burden of rare variants in synaptic genes in patients with severe tinnitus: An exome based extreme phenotype study

(2021) Sana Amanat et al.   EBioMedicine

Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation

(2020) Erik C. B. Johnson et al.   NATURE MEDICINE

MSstatsTMT: Statistical detection of differentially abundant proteins in experiments with isobaric labeling and multiple mixtures

(2020) Ting Huang et al.   MOLECULAR & CELLULAR PROTEOMICS

Inhibition of Hsp70 Suppresses Neuronal Hyperexcitability and Attenuates Epilepsy by Enhancing A-Type Potassium Current

(2019) Fang Hu et al.   Cell Reports

TMT labeling for the masses: A robust and cost-efficient, in-solution labeling approach

(2019) Jana Zecha et al.   MOLECULAR & CELLULAR PROTEOMICS

Precise detection of low-level somatic mutation in resected epilepsy brain tissue

(2019) Nam Suk Sim et al.   ACTA NEUROPATHOLOGICA

Dissecting the genetic basis of focal cortical dysplasia: a large cohort study

(2019) Sara Baldassari et al.   ACTA NEUROPATHOLOGICA

N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications

(2019) Joseph H. Neale et al.   PROGRESS IN NEUROBIOLOGY

Brain Somatic Mutations in MTOR Disrupt Neuronal Ciliogenesis, Leading to Focal Cortical Dyslamination

(2018) Sang Min Park et al.   NEURON

Data‐independent acquisition‐based SWATH‐MS for quantitative proteomics: a tutorial

(2018) Christina Ludwig et al.   Molecular Systems Biology

Myelination and mTOR

(2017) Gianluca Figlia et al.   GLIA

The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases

(2017) Rachel E. Lackie et al.   Frontiers in Neuroscience

An Optimized Shotgun Strategy for the Rapid Generation of Comprehensive Human Proteomes

(2017) Dorte B. Bekker-Jensen et al.   Cell Systems

A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease

(2017) Nicholas T. Seyfried et al.   Cell Systems

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

(2017) John J. Bissler et al.   PLoS One

Epilepsy-related sudden unexpected death: targeted molecular analysis of inherited heart disease genes using next-generation DNA sequencing

(2016) Yukiko Hata et al.   BRAIN PATHOLOGY

Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis

(2016) Klemens Budde et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

(2016) Jacqueline A French et al.   LANCET

The Perseus computational platform for comprehensive analysis of (prote)omics data

(2016) Stefka Tyanova et al.   NATURE METHODS

Modulation of nonsense mediated decay by rapamycin

(2016) Rocio T. Martinez-Nunez et al.   NUCLEIC ACIDS RESEARCH

Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer

(2016) Hui Guo et al.   Oncotarget

Novel Histopathological Patterns in Cortical Tubers of Epilepsy Surgery Patients with Tuberous Sclerosis Complex

(2016) Angelika Mühlebner et al.   PLoS One

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

(2016) David N. Franz et al.   PLoS One

Everolimus and sirolimus in transplantation-related but different

(2015) Jost Klawitter et al.   Expert Opinion On Drug Safety

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex

(2015) Jeffrey P. MacKeigan et al.   NEURO-ONCOLOGY

Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation

(2014) Damien Vitiello et al.   Cellular & Molecular Immunology

Suspension trapping (STrap) sample preparation method for bottom-up proteomics analysis

(2014) Alexandre Zougman et al.   PROTEOMICS

mTOR signaling and its roles in normal and abnormal brain development

(2014) Nobuyuki Takei et al.   Frontiers in Molecular Neuroscience

Metabolite Profiling of a NIST Standard Reference Material for Human Plasma (SRM 1950): GC-MS, LC-MS, NMR, and Clinical Laboratory Analyses, Libraries, and Web-Based Resources

(2013) Yamil Simón-Manso et al.   ANALYTICAL CHEMISTRY

mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation

(2013) Masahiro Morita et al.   Cell Metabolism

Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

(2013) Hope Northrup et al.   PEDIATRIC NEUROLOGY

Rapamycin Reverses Status Epilepticus-Induced Memory Deficits and Dendritic Damage

(2013) Amy L. Brewster et al.   PLoS One

Everolimus Triggers Cytokine Release by Macrophages

(2012) Wim Martinet et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Cell organization, growth, and neural and cardiac development require  II-spectrin

(2011) M. C. Stankewich et al.   JOURNAL OF CELL SCIENCE

Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment

(2011) Jürgen Cox et al.   JOURNAL OF PROTEOME RESEARCH

Software Lock Mass by Two-Dimensional Minimization of Peptide Mass Errors

(2011) Jürgen Cox et al.   JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY

Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials

(2011) Liset H. M. Pengel et al.   TRANSPLANT INTERNATIONAL

The clinicopathologic spectrum of focal cortical dysplasias: A consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission1

(2010) Ingmar Blümcke et al.   EPILEPSIA

The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

(2010) Jonathan H Fox et al.   Molecular Neurodegeneration

Direct control of mitochondrial function by mTOR

(2009) Arvind Ramanathan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function

(2008) L. Meikle et al.   JOURNAL OF NEUROSCIENCE

MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification

(2008) Jürgen Cox et al.   NATURE BIOTECHNOLOGY

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE